11/01/2024
8:24 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/31/2024
12:20 PM | FRANKLIN RESOURCES INC (Filed by)
Revance Therapeutics (Subject)
| Form SCHEDULE 13G/A | |
10/25/2024
7:49 PM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/23/2024
6:17 PM | GIC Private Ltd (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G/A | |
10/18/2024
8:29 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/07/2024
9:08 AM | Capital World Investors (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G/A | |
10/04/2024
6:32 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
|
09/23/2024
6:15 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/16/2024
4:01 PM | Beryl Capital Management LLC (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G | |
09/09/2024
9:40 AM | Capital World Investors (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G/A | |
09/05/2024
4:27 PM | Revance Therapeutics (Subject)
| Form SC14D9C | |
09/05/2024
3:45 PM | Crown Laboratories, Inc. (Filed by)
Revance Therapeutics (Subject)
| Form SC TO-C | |
08/13/2024
8:29 AM | Crown Laboratories, Inc. (Filed by)
Revance Therapeutics (Subject)
| Form SC TO-C | |
08/12/2024
4:18 PM | Revance Therapeutics (Subject)
| Form SC14D9C | |
08/12/2024
8:20 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/09/2024
8:00 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/08/2024
3:34 PM | Revance Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
07/02/2024
4:47 PM | Revance Therapeutics (Issuer)
Schilke Tobin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2024
4:47 PM | Foley Mark J (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2024
3:08 PM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/03/2024
7:42 AM | Beraud Jill (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/03/2024
7:43 AM | Coric Vlad (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/03/2024
7:44 AM | Gangolli Julian S (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/03/2024
7:45 AM | Kolaja Carey OConnor (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/03/2024
7:46 AM | Nolet Chris (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/03/2024
7:47 AM | Revance Therapeutics (Issuer)
Russell Angus C. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/03/2024
7:47 AM | Revance Therapeutics (Issuer)
Ware Olivia C (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/17/2024
3:34 PM | Jordan Erica (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/09/2024
12:17 PM | JPMORGAN CHASE & CO (Filed by)
JPMORGAN CHASE & CO (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G/A | |
03/19/2024
5:43 PM | Foley Mark J (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/19/2024
5:44 PM | Revance Therapeutics (Issuer)
Schilke Tobin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/19/2024
5:44 PM | Moxie Dwight (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/19/2024
5:45 PM | Revance Therapeutics (Issuer)
Sjuts Dustin S (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2024
5:16 AM | Revance Therapeutics (Subject)
Sjuts Dustin S (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/18/2024
5:10 AM | Moxie Dwight (Reporting)
Revance Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/18/2024
5:13 AM | Revance Therapeutics (Subject)
Schilke Tobin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/08/2024
3:33 PM | Foley Mark J (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/05/2024
4:08 PM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/04/2024
4:33 PM | Moxie Dwight (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/04/2024
3:44 PM | Revance Therapeutics (Issuer)
Schilke Tobin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/04/2024
3:33 PM | Foley Mark J (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad) As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential.
Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention. 👉 Click here to access your FREE report now! |
03/04/2024
5:39 AM | Revance Therapeutics (Filer)
| Form 424B5 | |
02/29/2024
3:32 PM | Hollander David (Reporting)
Revance Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
02/29/2024
3:36 PM | Jordan Erica (Reporting)
Revance Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
02/28/2024
3:07 PM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/14/2024
3:55 PM | Palo Alto Investors LP (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G/A | |
02/14/2024
2:45 PM | Antara Capital LP (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G/A | |
02/13/2024
8:39 AM | Polar Capital Holdings Plc (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G/A | |
02/09/2024
5:21 PM | Capital World Investors (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G/A | |
02/09/2024
9:05 AM | GIC Private Ltd (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G/A | |
02/06/2024
12:58 PM | FRANKLIN RESOURCES INC (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G | |
02/02/2024
3:46 PM | Revance Therapeutics (Issuer)
Schilke Tobin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
3:48 PM | Moxie Dwight (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
3:45 PM | Foley Mark J (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/25/2024
10:10 AM | JPMORGAN CHASE & CO (Filed by)
JPMORGAN CHASE & CO (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G/A | |
01/25/2024
10:11 AM | JPMORGAN CHASE & CO (Filed by)
JPMORGAN CHASE & CO (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G/A | |
01/08/2024
7:01 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/03/2024
3:50 PM | Revance Therapeutics (Issuer)
Sjuts Dustin S (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/18/2023
3:32 PM | Revance Therapeutics (Issuer)
Sjuts Dustin S (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
